Recent News

• 08.06.2026 - Customer success story: How CHU Nîmes went from install to routine rare disease use in three months
• 08.05.2026 - PacBio Appoints Mark Van Oene as President and Chief Executive Officer
• 08.05.2026 - PacBio Announces Second Quarter 2026 Financial Results
• 08.05.2026 - PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
• 07.30.2026 - APAC PRISM 2026 highlights: Advancing research with HiFi sequencing
• 07.28.2026 - PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
• 07.28.2026 - The practical value of long-range PCR for targeted HiFi sequencing
• 07.23.2026 - Meet the winner of the 2026 SMRT Grant for long-read cancer multiomics for clinical research and drug discovery
• 07.16.2026 - Why long reads are changing how researchers approach targeted sequencing
• 07.15.2026 - PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026

Recent Filings

• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2026 - 8-K Current report
• 08.05.2026 - EX-99.1 EX-99.1
• 07.09.2026 - 8-K Current report
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities